Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

SEAS: Simvastatin and EZETimibe in aortic stenosis

principal contacts

Terje Pedersen (University of Oslo)

Yale Mitchel (Merck &Co. Inc)

Andrew Tershakovec (Merck and Co. Inc.)


Merck & Co. Inc


Merck & Co. Inc.

key publications

Design and baseline characteristics: Am J Cardiol 2007;99:970 –973

Main results: N Engl J Med 2008;359:1343-56

Analyses of Cancer Data from Three Ezetimibe Trials: N Engl J Med 2008;359:1357-66

Observed and predicted reduction in CV events: Am J Cardiol 2010; 105(12):1802-8

Impact of baseline severity of aortic stenosis: Am J Cardiol 2010; 106(11):1634-9

Prognostic importance of atrial fibrillation: Int J Cardiol 2013; 166(1): 72-6

Incidence of cancer and mortality: Am J Cardiol 2014; 114(10): 1518-22

Effect on cataract: Am J Cardiol 2015; 166(12): 1840-4